Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

9 Nov 2016 09:36

RNS Number : 7388O
Diurnal Group PLC
09 November 2016
 

9 November 2016

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them in accordance with the Market Abuse Regulations.

 

On 8 November 2016 the following par value options over ordinary shares of 5 pence in Diurnal were granted under the Diurnal Group plc Long Term Incentive Plan (the "Plan") to persons discharging managerial responsibilities ("PDMR"):

 

PDMR

Total no. of shares under award

Type of awards

Martin Whitaker

133,333

Performance Share Award

Martin Whitaker

69,565

Deferred Bonus Award

Ian Ardill

81,250

Performance Share Award

Ian Ardill

22,608

Deferred Bonus Award

 

The performance share awards will ordinarily vest no earlier than the third anniversary of their grant subject to the grantee's continued service and to the extent to which the performance conditions set for the awards are satisfied. Such awards may potentially vest until the fifth anniversary of their grant date.

 

The deferred bonus awards will ordinarily vest on the first anniversary of their grant subject to the grantee's continued service.

 

The awards were granted under award agreements that incorporated the terms of the Plan and comprised a mix of tax-favoured 'EMI' awards and non-tax favoured awards.

 

The exercise price payable per share under award is par value presently being 5 pence per ordinary share.

 

Details of the full notifications received by the Company are set out below:

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Martin Whitaker

2

Reason for Notification

a)

Position/status

Chief Executive Officer

b)

Initial notification/Amendment

Initial Announcement

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Diurnal Group plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 5 pence each in Diurnal Group plc

GB00BDB6Q760

b)

Nature of the transaction

Grant of awards under the Diurnal Group plc Long Term Incentive Plan as par value options as follows:

 

Non-EMI performance share award over 133,333 ordinary shares.

 

EMI deferred bonus award over 9,730 ordinary shares.

 

Non-EMI deferred bonus award over 59,835 ordinary shares.

 

The performance share award will ordinarily vest no earlier than the third anniversary of its grant subject to continued service and to the extent to which the performance conditions set for the awards are satisfied. Such award may potentially vest until the fifth anniversary of its grant date.

 

The deferred bonus awards will ordinarily vest on the first anniversary of their grant subject to continued service.

 

The exercise price payable per share under award is par value presently being 5 pence per ordinary share.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

133,333

Nil

9,730

Nil

59,835

d)

Aggregated information

- Aggregated volume

- Price

Award over total of 202,898 ordinary shares. Nil price payable for grant.

e)

Date of the transaction

8 November 2016

f)

Place of the transaction

Outside a trading venue

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Ian Ardill

2

Reason for Notification

a)

Position/status

Chief Financial Officer

b)

Initial notification/Amendment

Initial Announcement

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Diurnal Group plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 5 pence each in Diurnal Group plc

GB00BDB6Q760

b)

Nature of the transaction

Grant of awards under the Diurnal Group plc Long Term Incentive Plan as par value options as follows:

 

EMI performance share award over 53,323 ordinary shares.

 

Non-EMI performance share award over 27,927 ordinary shares.

 

EMI deferred bonus award over 22,608 ordinary shares.

 

The performance share awards will ordinarily vest no earlier than the third anniversary of their grant subject to continued service and to the extent to which the performance conditions set for the awards are satisfied. Such awards may potentially vest until the fifth anniversary of their grant date.

 

The deferred bonus award will ordinarily vest on the first anniversary of its grant subject to continued service.

 

The exercise price payable per share under award is par value presently being 5 pence per ordinary share.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

53,323

Nil

27,927

Nil

22,608

d)

Aggregated information

- Aggregated volume

- Price

Award over total of 103,858 ordinary shares. Nil price payable for grant.

e)

Date of the transaction

8 November 2016

f)

Place of the transaction

Outside a trading venue

 

 

 

For further information, please visit www.diurnal.co.uk or contact:

Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, CEO

Ian Ardill, CFO

Numis Securities Ltd (Nominated Adviser)

+44 (0)20 7260 1000

Nominated Adviser: Michael Meade, Freddie Barnfield, Paul Gillam

Corporate Broking: James Black

FTI Consulting

+44 (0)20 3727 1000

Simon Conway

Victoria Foster Mitchell

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHFSMSUUFMSEDF
Date   Source Headline
9th Jan 20187:00 amRNSPositive results from Alkindi food matrix study
9th Jan 20187:00 amRNSBusiness Update and Notice of Interim Results
5th Jan 20185:06 pmRNSIssue of Equity
5th Jan 20185:04 pmRNSReplacement - Director Dealings
5th Jan 20181:19 pmRNSDirector Dealings
19th Dec 201712:53 pmRNSHardman Research: Alkindi®: On route to Europe
15th Dec 201712:50 pmRNSDiurnal receives positive CHMP opinion for Alkindi
15th Dec 201712:11 pmRNSCHMP positive opinion for Alkindi® (Infacort®)
8th Dec 201711:30 amRNSTotal Voting Rights
29th Nov 201712:20 pmRNSDirector/PDMR Shareholding
21st Nov 201712:00 pmRNSResult of AGM
9th Nov 20176:19 pmRNSDirector Dealing and Issue of Equity
8th Nov 201712:00 pmRNSDirector/PDMR Shareholding
13th Oct 20179:00 amRNSPosting of Annual Report and AGM Notice
15th Sep 20177:00 amRNSInfacort® data published in Clinical Endocrinology
14th Sep 20177:15 amRNSHardman Research: Ready to press the button
7th Sep 20172:51 pmRNSDirector Dealings
6th Sep 20177:00 amRNSGrant of first US patent for Chronocort®
6th Sep 20177:00 amRNSResults for the year ended 30 June 2017
14th Aug 201710:00 amRNSNotice of Final Results
15th Jun 20177:00 amRNSFirst Patient Dosed in US Infacort Clinical Trial
18th May 20177:00 amRNSGrant of first US patent for Infacort
8th May 201710:03 amRNSDirector/PDMR Shareholding
27th Mar 20177:15 amRNSHardman Research:Commercial and development update
20th Mar 20177:00 amRNSInterim Results for the 6 Months Ended 31 Dec 2016
16th Mar 20177:00 amRNSLaunch of a European Patient Access programme
2nd Mar 20177:00 amRNSMarketing and Distribution Agreement
1st Mar 20177:00 amRNSNotice of Interim Results
20th Feb 20177:00 amRNSAppointment of Joint Broker
25th Jan 20177:00 amRNSUpdate on Commercial Pre-Launch Activities
19th Jan 20177:15 amRNSHardman Research: Infacort® - On track to market
17th Jan 20173:30 pmRNSDirector Dealings
16th Jan 20177:00 amRNSDirectors' Dealings
12th Jan 20177:00 amRNSAppointment of Chief Financial Officer
4th Jan 20173:38 pmRNSHolding(s) in Company
20th Dec 201612:08 pmRNSSubmission of Infacort® European PUMA Application
23rd Nov 201611:30 amRNSResults of Annual General Meeting
21st Nov 20167:00 amRNSFirst Patient Dosed in Testosterone Trial
9th Nov 20169:36 amRNSDirector/PDMR Shareholding
27th Oct 20167:15 amRNSHardman Research: Get the Rhythm
12th Oct 20167:00 amRNSFull Infacort Phase III Data Analysis
12th Oct 20167:00 amRNSFinal Results June 2016
12th Sep 20167:00 amRNSNotice of Results
11th Jul 20167:00 amRNSPositive headline data Infacort pivotal study
12th Apr 201612:15 pmRNSGrants of options and award of conditional shares
30th Mar 20167:00 amRNSHalf Yearly Report
22nd Mar 20163:00 pmRNSNotice of Results
29th Feb 20167:00 amRNSFirst patient dosed in Chronocort® pivotal study
19th Jan 20163:32 pmRNSHolding(s) in Company
5th Jan 20163:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.